Journal of Addictive Diseases最新文献

{"title":"Management of treatment-refractory opioid use disorder: a case-series of a modified maintenance protocol.","authors":"William Rioux, Jeremy Weleff, Cristina Zaganelli, Lovneet Hayer, Sumantra Monty Ghosh","doi":"10.1080/10550887.2025.2581489","DOIUrl":"10.1080/10550887.2025.2581489","url":null,"abstract":"<p><strong>Background and objectives: </strong>Reaching the maintenance phase and reducing illicit substance use in those with severe opioid use disorder (OUD) remains a large clinical challenge. The use of intravenous opioid agonist treatment has become a last-line treatment for severe OUD. In this case series, we describe a novel form of this treatment using both long-acting buprenorphine and injectable hydromorphone.</p><p><strong>Methods: </strong>Retrospective chart review of cases in specialized enhanced addiction treatment centers in Alberta, Canada of patients prescribed long-acting injectable buprenorphine and intravenous hydromorphone.</p><p><strong>Results: </strong>We describe four cases of males ranging from 39 to 64 years of age with treatment-refractory opioid use disorder and multiple concurrent mental health and social issues who have experienced various periods of stability on long-acting injectable buprenorphine and along with intravenous hydromorphone or slow release oral morphine).</p><p><strong>Discussion and conclusions: </strong>This case series presents a novel treatment combining buprenorphine extended-release injection with hydromorphone or slow release oral morphine for individuals with OUD who have not responded to standard opioid agonist treatment. The approach showed promise in managing withdrawal and cravings, potentially improving treatment retention. Further research is needed to evaluate long-term outcomes and optimize retention strategies to reduce opioid-related mortality.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"351-357"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145565761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mephentermine misuse: an emerging challenge and the potential role of mirtazapine-a case report.","authors":"Reshma Dcruz, Aravind Karunakaran, Aparna Sasikumar, Sandeep Alex, Smitha Ramadas","doi":"10.1080/10550887.2025.2514287","DOIUrl":"10.1080/10550887.2025.2514287","url":null,"abstract":"<p><p>Mephentermine is a sympathomimetic amine with structural and pharmacological similarities to amphetamines. Despite its increasing misuse, particularly among athletes and bodybuilders, there is limited literature on its management. No pharmacological treatments have been approved for mephentermine misuse. We describe two cases of young adult males presenting with symptoms of mephentermine withdrawal, including insomnia, anxiety, and craving. Both had histories of prolonged intravenous mephentermine use, with one managed on an outpatient basis and the other as an inpatient. Mirtazapine was initiated in both cases and was associated with improvements in sleep, anxiety, craving and hyperarousal. Psychotic symptoms in one patient resolved with short-term risperidone. Both patients received brief motivational enhancement therapy and remained abstinent from all substances except tobacco during two months of follow-up. These cases highlight the potential utility of mirtazapine in managing mephentermine misuse, particularly for addressing withdrawal symptoms and craving. Given its noradrenergic and serotonergic profile and its demonstrated efficacy in methamphetamine use, mirtazapine may be a promising candidate for treatment. However, the findings are limited by the case series design and larger, controlled studies are needed to confirm its role in clinical management.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"358-363"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Referrals offered to affected family members: a cross-sectional analysis of a substance use program register.","authors":"Júlia Ramil Soeiro E Silva, Ronaldo Laranjeira, Martha Canfield, Claudio Jerônimo da Silva, Raquel Radaeli de Figueiredo Molen, Helena Takeyama Sakiyama, Douglas José Resende Lima, Maria de Fatima Rato Padin","doi":"10.1080/10550887.2025.2514325","DOIUrl":"10.1080/10550887.2025.2514325","url":null,"abstract":"<p><p><b>Background:</b> Demand is growing for support services for affected family members (AFM) of relatives with a substance use disorder or problematic substance use. This study examined referral patterns and factors influencing referral types of AFM who sought support through the program '<i>Recomeço Família'</i> in São Paulo, Brazil. <b>Methods</b>: A cross-sectional retrospective analysis of 5,192 records of family members registered in the program between 2014 and 2018. Referrals made by health professionals to external services were assessed and factors associated with referral types were assessed through univariate binary logistic regressions. <b>Results:</b> Most of the referrals were to individual therapies (counseling/psychotherapy)(64.30%), followed by family support groups (21.15%) and psychoeducational programs (14.55%). Referral destinations varied by AFM and their relative characteristics, including gender, age, kinship, levels of emotional distress, help-seeking history and substance type. <b>Conclusion</b>: The findings highlight factors that may influence referral decisions and underscore the need for further investigation into whether these referrals effectively address the specific needs of AFM.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"342-346"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence that hedonic response toward sugar in alcohol use disorder is mediated by antidepressant use and does not constitute an endophenotype.","authors":"Alexandra Dereux, Clément Vansteene, Stéphanie Dubal, Héline Kaya Lefevre, Daphnée Poupon, Nicolas Ramoz, Philip Gorwood","doi":"10.1080/10550887.2025.2533575","DOIUrl":"10.1080/10550887.2025.2533575","url":null,"abstract":"<p><strong>Background: </strong>Literature highlighted a higher sweet preference among patients with alcohol use disorder (AUD) that may act as an endophenotypical vulnerability. However, results remain heterogenous and seldom information is available regarding possible origins, such as hedonic abilities, reward sensitivity or impulsivity.</p><p><strong>Objective: </strong>This cross-sectional study aims to explore the relationship between AUD and sweet preference as well as its endophenotypical properties.</p><p><strong>Methods: </strong>Ninety-two participants were divided into three groups (36 patients with AUD, 29 healthy controls and 27 healthy first-degree relatives), and were asked to take a sweet preference test, a hedonic test, the <i>Iowa Gambling Task</i> (IGT) and self-reported inventories measuring impulsivity (<i>Barratt Impulsiveness Scale</i> [BIS-11]), anxiety and depression (<i>Hospital Anxiety and Depression scale</i> [HADS]). A stepwise linear regression with all available variables was performed to compare patients and controls. Factors included in the retained model were then added as mediators in a path analysis.</p><p><strong>Results: </strong>Compared to healthy controls, patients with AUD had a lower sweet score. The difference lost its significance in the linear regression: the retained model only included antidepressant use (<i>p</i> = .016) and tobacco use status (<i>p</i> = 0.074). The path analysis showed that antidepressant use, but not tobacco use status, significantly mediated the effect of AUD on sweet preference. Sweet score did not significantly differ between first-degree relatives and the two other groups.</p><p><strong>Conclusions: </strong>Our results do not support the hypothesis that sweet preference is an endophenotype of AUD. Instead, they suggest that the association between sweet preference and AUD may be mediated by confounding factors such as antidepressant use.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"327-335"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"President's message: the perilous illusion of supervised injection sites.","authors":"Darrin Mangiacarne","doi":"10.1080/10550887.2026.2680828","DOIUrl":"10.1080/10550887.2026.2680828","url":null,"abstract":"","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"233-234"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148220130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Buprenorphine-naloxone vs methadone for opioid use disorder: a systematic review and meta-analysis of randomized clinical trials.","authors":"Anderson Matheus Pereira da Silva, Mariana Leticia de Bastos Maximiano, Lucas Silva Cabeça, Levi Leal Silva, Elizabeth Honorato de Faria, Matheus Nepomuceno Fernandes, Ariane Barros Mesquita Cunha, Gabrielle Silva Vieira, Thierry Duarte Ribeiro Sobral, Daniel Vicente de Siqueira Lima Júnior, Maria Bernadete de Sousa Maia, Eryvelton de Souza Franco","doi":"10.1080/10550887.2025.2514308","DOIUrl":"10.1080/10550887.2025.2514308","url":null,"abstract":"<p><p><b>Background:</b> This meta-analysis evaluated the efficacy and safety of buprenorphine-naloxone compared to methadone in the treatment of Opioid Use Disorder (OUD), with a focus on treatment retention, attrition rates, and serious adverse events. OUD remains a major public health concern, necessitating effective pharmacological interventions to improve adherence and minimize adverse outcomes.<b>Methods:</b> A systematic search of PubMed, Embase, Cochrane CENTRAL, Web of Science, and Scopus identified randomized controlled trials comparing both treatments. The study adhered to PRISMA guidelines, and data were analyzed using a random-effects model with Odds Ratios (OR) and 95% Confidence Intervals (CI). Heterogeneity was assessed using the I² statistic.<b>Results:</b> Seven randomized controlled trials involving 3,622 patients were included. Methadone doses ranged from 5 to 397 mg/day and buprenorphine-naloxone from 2 to 32 mg/day. Methadone showed significantly higher treatment retention at six months compared to buprenorphine-naloxone (OR 0.43; 95% CI 0.27-0.67; I² = 62.2%). Attrition was higher in the buprenorphine-naloxone group (OR 2.47; 95% CI 1.42-4.30; I² = 68.4%). In contrast, serious adverse events occurred less frequently with buprenorphine-naloxone (OR 0.72; 95% CI 0.48-1.09; I² = 0.0%).<b>Conclusion:</b> In conclusion, methadone is associated with superior retention, while buprenorphine-naloxone presents a more favorable safety profile. These findings highlight the need for individualized treatment decisions based on clinical context and patient-specific risks. Future large-scale, high-quality studies are recommended to guide optimal pharmacological strategies for managing OUD.</p><p><strong>Registration: </strong>PROSPERO protocol number: CRD 42025634919.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"246-256"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring and management of injection site reactions in patients receiving subcutaneous buprenorphine (Sublocade): two case reports and literature review.","authors":"Hina Fawad, Jennifer Casarella, Yi-Lang Tang","doi":"10.1080/10550887.2025.2555636","DOIUrl":"10.1080/10550887.2025.2555636","url":null,"abstract":"<p><strong>Introduction: </strong>Injectable extended-release buprenorphine is an effective treatment for opioid use disorder (OUD), but injection site reactions (ISRs) are common treatment-emergent adverse events that may impact patient comfort, adherence, and outcome. This report examines the clinical presentation, prevalence, and management of Sublocade-related ISRs through two case studies and a review of existing literature.</p><p><strong>Case presentation: </strong>We present two cases of ISRs in patients receiving extended-release buprenorphine, Sublocade. The first involves a 65-year-old male who experienced localized pain, swelling, and erythema after the injection. The second case features a 58-year-old male with injection site swelling, tenderness, and presumed cellulitis. We also examine ISR prevalence and severity from clinical trials and real-world data.</p><p><strong>Management & outcomes: </strong>Both patients received timely care and responded well to appropriate interventions. The first case was managed conservatively with cold compresses, topical hydrocortisone, and ibuprofen, resulting in symptom resolution. The second case required oral antibiotics after ultrasound imaging revealed a subcutaneous fluid collection; the cellulitis resolved without systemic complications.</p><p><strong>Conclusion: </strong>While ISRs associated with Sublocade are common, most are manageable with conservative interventions. Emphasizing patient education, proper injection techniques, and site rotation is essential to prevent ISRs, minimize their severity, and enhance treatment outcomes in patients with OUD.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"372-376"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The perils of marijuana use in adolescents.","authors":"Savitra Ward, Sanjana Konda, Daniel Zongliang Zhao, Latha Ganti","doi":"10.1080/10550887.2025.2589700","DOIUrl":"10.1080/10550887.2025.2589700","url":null,"abstract":"<p><strong>Background: </strong>Marijuana usage is on the rise. It is becoming more dangerous because of the significantly greater amounts of tetrahydrocannabinol (THC) and more accessible because of legalization. This paper aims to examine the usage of cannabis in adolescents aged 12-17 and determine the multifaceted effects and dangers that come with the usage.</p><p><strong>Methods: </strong>This study queried data from the National Survey on Drug Use and Health. The database was queried and tested until significant numbers were found. Age was added as a control variable to ensure the data was of just adolescents aged 12-17 and not a wide array of ages. We compared adolescents who use marijuana to adolescents who did not use marijuana in four topics: gender, race, number of school days missed,and grades.</p><p><strong>Results: </strong>The overall pooled prevalence of cannabis use in adolescents ages 12-17 is 11.4% (95% CI: 10.70-12.20%). Cannabis use was slightly more prominent among females than males and in white adolescents, Hispanics, and blacks. The higher the marijuana use, the more likely adolescents are to skip class and the less likely they are to perform well grade-wise.</p><p><strong>Conclusion: </strong>Approximately 1 in 10 individuals who try marijuana get develop a use disorder.When narrowing the pool down to just teenagers, that number increases to one in six adolescentswho try marijuana being with marijuana addiction.Therefore, there is a need to educate teenagers and their families about the effects and consequences of marijuana use. These consequences are greater and more severe than most think.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"336-341"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145999395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing cannabis use among adolescents seeking treatment for their substance use.","authors":"Prianka Kumar, Emma Straton, Sivabalaji Kaliamurthy","doi":"10.1080/10550887.2025.2528314","DOIUrl":"10.1080/10550887.2025.2528314","url":null,"abstract":"<p><strong>Introduction: </strong>The evolving landscape of laws and policies related to cannabis can inform patterns and trends in adolescent cannabis use. Today, a wide variety of cannabis products and alternatives are available in the legal and illicit markets. Harms associated with their use may vary depending on the amount and type of tetrahydrocannabinol (THC) they contain. Few studies have examined the awareness of and use of these different cannabis products among adolescents.</p><p><strong>Methods: </strong>Our study examined patterns of cannabis use in adolescent patients of an urban pediatric addiction clinic.</p><p><strong>Results: </strong>Most adolescents seen at the clinic use multiple cannabis products, and many adolescents use cannabinoid derivatives such as delta-8 and delta-10 THC.</p><p><strong>Discussion: </strong>These results highlight the need for providers to explore in depth the various cannabis products used by adolescents, educate adolescents on the products, especially due to unknown risks associated with cannabinoid derivatives, and advocate for further regulation of alternative cannabis products.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"347-350"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smoking initiation as a mediator: investigating the causal relationship between sedentary lifestyles and cannabis use disorder through Mendelian randomization.","authors":"Deyu Meng, Meiqi Wei, Shichun He, Zongnan Lv, Hongtu Zhang, Guang Yang, Ziheng Wang","doi":"10.1080/10550887.2025.2516290","DOIUrl":"10.1080/10550887.2025.2516290","url":null,"abstract":"<p><strong>Background: </strong>Cannabis Use Disorder (CUD) involves compulsive cannabis use, leading to significant impairment and distress. Previous research indicates lower physical activity and higher sedentary behavior among cannabis users, but the causal relationship remains unclear. This study aims to use Mendelian randomization (MR) to investigate the causal link between exercise, sedentariness, and CUD.</p><p><strong>Methods: </strong>We analyzed genetic associations for (1) moderate-to-vigorous physical activity (MVPA), (2) leisure screen time (LST), (3) sedentary commuting behavior (SCB), and (4) sedentary behavior at work (SBW). Genetic instruments for smoking initiation were identified from the GSCAN study. Genetic associations for CUD were derived from the largest Genome-wide association studies (GWAS) of CUD. We selected significant genetic variants, harmonized data. We conducted MR analyses using IVW, assessing heterogeneity and pleiotropy with Cochran's Q test and MR-Egger regression, and performed leave-one-out analyses.</p><p><strong>Results: </strong>SBW showed a protective causal relationship with CUD (OR = 0.61, 95% CI = 0.42-0.90, <i>p</i> = 0.012). LST increased the risk of CUD (OR = 1.43, 95% CI = 1.20-1.70, <i>p</i> < 0.001). LST also showed a significant causal relationship with smoking initiation (OR = 1.28, 95% CI = 1.21-1.36, <i>p</i> < 0.001), which was associated with increased CUD risk. Smoking initiation mediated 54.08% of the increased CUD risk associated with LST (95% CI = 53.72-54.44%).</p><p><strong>Conclusions: </strong>A sedentary lifestyle may lead to CUD through smoking. Addressing sedentariness and promoting physical activity may reduce the risk of smoking initiation and subsequent cannabis-related problems.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"267-277"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144592664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}